Promising Pipeline and Strategic Collaborations Fuel Buy Rating for Silence Therapeutics
TipRanks (Wed, 29-Jan 12:15 PM ET)
Business Wire (Mon, 9-Dec 7:30 AM ET)
Business Wire (Tue, 26-Nov 8:00 AM ET)
Business Wire (Mon, 18-Nov 2:30 PM ET)
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Business Wire (Thu, 14-Nov 8:00 AM ET)
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Business Wire (Wed, 13-Nov 8:00 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of January 31, 2025, SLN stock price climbed to $5.35 with 41,265 million shares trading.
SLN has a beta of 0.57, meaning it tends to be less sensitive to market movements. SLN has a correlation of 0.01 to the broad based SPY ETF.
SLN has a market cap of $252.60 million. This is considered a Small Cap stock.
In the last 3 years, SLN traded as high as $27.72 and as low as $4.55.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, BBC, GWX, BIB, IBBQ.
SLN has underperformed the market in the last year with a return of -72.6%, while the SPY ETF gained +25.4%. In the last 3 month period, SLN fell short of the market, returning -69.1%, while SPY returned +5.3%. However, in the most recent 2 weeks SLN has outperformed the stock market by returning +6.4%, while SPY returned +2.9%.
SLN support price is $4.87 and resistance is $5.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.